Brian Schumer joins SOFIE as Chief Operating Officer
We are excited to welcome Brian Schumer to the SOFIE team. Brian joins SOFIE […]
SOFIE affiliate, iTheranostics, executes agreement for its promising library of Fibroblast Activation Protein (FAP) targeted theranostics
- Novartis has acquired global development and commercial rights to therapeutic applications for iTheranostics’ library […]
SOFIE Inc. enters into partnership with AUGMENTICON™
AUGMENTICON™, a privately held technology company developing Augmented-/Mixed-Reality (AR-/MR)-tools for a cost-effective, high-quality manufacturing […]
FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients GalleryFAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
![68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT](https://sofie.com/wp-content/uploads/2021/04/68-Ga-NOTA-FAPI-04-PETCT-in-a-patient-with-primary-gastric-diffuse-large-B-cell-lymphoma-comparisons-with-FDG-PETCT.jpg)
![[ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions](https://sofie.com/wp-content/uploads/2021/04/18-FFDG-and-68-GaGa-DOTA-FAPI-04-PETCT-in-the-evaluation-of-tuberculous-lesions.png)
